Amlodipine/Telmisartan Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Amlodipine/Telmisartan Availability in 2026

If your patients have been reporting difficulty filling Amlodipine/Telmisartan prescriptions, their frustration is well-founded. The combination product — formerly branded as Twynsta — has been experiencing persistent availability challenges that warrant proactive prescribing strategies.

This briefing covers the current supply landscape, clinical considerations for switching, and tools that can help your patients access their medication.

Timeline: How We Got Here

The supply disruption traces back to two key events:

• Twynsta brand discontinuation: Boehringer Ingelheim discontinued the branded Twynsta product, leaving the market dependent entirely on generic manufacturers.
• Limited generic manufacturing base: Unlike high-volume monotherapy generics (Amlodipine alone has multiple manufacturers and costs under $5), the Telmisartan/Amlodipine combination has a smaller manufacturer base. This makes supply more vulnerable to disruptions at any single production facility.

The FDA currently lists Telmisartan and Amlodipine tablets under a "Discontinuation" status for the branded product. Generic versions remain available but with inconsistent distribution, particularly for the 40/10 mg and 80/10 mg strengths.

Prescribing Implications

The intermittent availability of Amlodipine/Telmisartan has several clinical implications:

Adherence Risk

Patients who cannot fill their combination tablet may go days or weeks without adequate blood pressure control. Combination products are prescribed specifically because these patients need dual-mechanism therapy — interruptions can lead to blood pressure rebound and increased cardiovascular risk.

Pill Burden Considerations

The primary advantage of the fixed-dose combination is adherence through simplicity. If patients must switch to taking Amlodipine and Telmisartan as separate tablets, the clinical effect is equivalent, but the adherence benefit of single-pill therapy is lost. For patients with complex medication regimens, this matters.

Formulary and Prior Authorization

Most insurance formularies cover generic Telmisartan/Amlodipine on Tier 2 or Tier 3 without prior authorization. However, if switching to an alternative combination (e.g., Olmesartan/Amlodipine or Valsartan/Amlodipine), verify formulary coverage to avoid cost barriers for your patients.

Current Availability Picture

As of early 2026, the supply situation can be summarized as:

• Generic Telmisartan/Amlodipine: Available but inconsistently stocked. Larger chain pharmacies may not carry it routinely; independent pharmacies and mail-order services tend to have better availability.
• Individual components: Both Amlodipine (generic) and Telmisartan (generic) are widely available with no supply concerns. Prescribing the two separately is the most reliable way to ensure patient access.
• Alternative combinations: Valsartan/Amlodipine and Olmesartan/Amlodipine are widely available in generic form.

Cost and Access Considerations

Cost can be a barrier, particularly for uninsured patients or those with high-deductible plans:

• Generic Telmisartan/Amlodipine combination: $120-$250 retail; approximately $123 with GoodRx coupon
• Separate generics: Amlodipine $3-$10/month + Telmisartan $15-$30/month = $18-$40/month total
• Valsartan/Amlodipine generic: $20-$60/month with discount card

For patients with financial hardship, the Boehringer Ingelheim Cares Foundation offers patient assistance for qualifying individuals. NeedyMeds and RxAssist also list assistance programs. Additional savings strategies are available in our provider's guide to saving patients money on Amlodipine/Telmisartan.

Tools and Resources for Your Practice

Several tools can help streamline the process of getting your patients their medication:

Medfinder for Providers

Medfinder offers a provider-facing tool that helps locate pharmacies with specific medications in stock. You or your staff can use it to direct patients to pharmacies that currently carry Amlodipine/Telmisartan, reducing failed fill attempts and patient callbacks.

Prescribing Strategy

Consider the following workflow for patients on Amlodipine/Telmisartan:

1. Primary prescription: Amlodipine/Telmisartan combination at the current dose
2. Backup plan: If the combination is unavailable, authorize the pharmacy to dispense the components separately at equivalent doses
3. Document the backup in the patient's chart so the pharmacy can proceed without calling for a new prescription

Patient Education

Equip patients with resources to self-advocate:

• Recommend they use Medfinder to check pharmacy stock before going to the pharmacy
• Suggest requesting refills 7-10 days before running out
• Advise trying independent or mail-order pharmacies if chains are out

Looking Ahead

The approval of Widaplik (Telmisartan/Amlodipine/Indapamide) in late 2025 adds a new option for patients who need aggressive blood pressure management. This triple combination may be worth considering for patients already on Amlodipine/Telmisartan who need additional reduction, though it introduces a diuretic component that requires monitoring.

As the generic market stabilizes and potentially adds more manufacturers, availability of the dual combination should improve. In the meantime, proactive prescribing — including backup plans for the individual components — remains the most effective way to protect your patients from supply disruptions.

Final Thoughts

The Amlodipine/Telmisartan supply challenge requires prescribers to be proactive rather than reactive. Build backup plans into your prescribing workflow, familiarize your staff with tools like Medfinder for Providers, and ensure patients understand their options when the combination isn't available.

For a practical workflow guide, see how to help your patients find Amlodipine/Telmisartan in stock.